These targets were selected to represent diverse tumor scenarios, with varying expression of surface CAR target antigens (i.e., CD70) and NKR ligands (e.g., MICA/B, ULBPs, CD112, and CD155), thus modeling RCC-associated tumor heterogeneity. This evidence concerns the gene NECTIN2 and renal cell carcinoma.